Go offline with the Player FM app!
🧬 Risk, Recurrence, Relief: Apixaban’s Edge in VTE 🌡️ Emphasizes the risk stratification, recurrence data, and therapeutic benefit
Manage episode 504095638 series 2740117
🩺 New Insights on Apixaban for VTE!
📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE.
📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding.
🎯 Editorial in NEJM urges a shift from binary labels (“provoked vs unprovoked”) to a patient-centered, risk-adapted approach.
🧠 Art meets evidence in the decision to extend anticoagulation.
💬 Let’s rethink how we label, risk-stratify, and treat.
📚 #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine #SharedDecisionMaking #EvidenceBasedMedicine #Cardiology
707 episodes
Manage episode 504095638 series 2740117
🩺 New Insights on Apixaban for VTE!
📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE.
📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding.
🎯 Editorial in NEJM urges a shift from binary labels (“provoked vs unprovoked”) to a patient-centered, risk-adapted approach.
🧠 Art meets evidence in the decision to extend anticoagulation.
💬 Let’s rethink how we label, risk-stratify, and treat.
📚 #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine #SharedDecisionMaking #EvidenceBasedMedicine #Cardiology
707 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.